Publication List 2002

1984-94, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022

15 （238）	Miyazono K. Bone morphogenetic protein receptors and actions. In: Principles of Bone Biology, Second ed., vol. 2. (Bilezikian, J.P., Raisz, L.G., and Rodan, G.A. eds.), pp. 929-942.
14 （237）	Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major Smad pathways in TGF-β superfamily signalling. Genes Cells. 2002 Dec;7(12):1191-204.
13 （236）	Ota T, Fujii M, Sugizaki T, Ishii M, Miyazawa K, Aburatani H, Miyazono K. Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-β in human umbilical vein endothelial cells. J Cell Physiol. 2002 Dec;193(3):299-318.
12 （235）	Miyazono K. Regulation of transforming growth factor-β signaling and vascular diseases. Cornea. 2002 Oct;21(7 Suppl):S48-53.
11 （234）	Suzuki C, Murakami G, Fukuchi M, Shimanuki T, Shikauchi Y, Imamura T, Miyazono K. Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J Biol Chem. 2002 Oct 18;277(42):39919-25.
10 （233）	Hamamoto T, Beppu H, Okada H, Kawabata M, Kitamura T, Miyazono K, Kato M. Compound disruption of smad2 accelerates malignant progression of intestinal tumors in apc knockout mice. Cancer Res. 2002 Oct 15;62(20):5955-61.
9 （232）	Nishihara A, Watabe T, Imamura T, Miyazono K. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell. 2002 Sep;13(9):3055-63.
8 （231）	Miyazono K, Miyazawa K. Id: a target of BMP signaling. Sci STKE. 2002 Sep 24;2002(151):pe40.
7 （230）	Shen ZJ, Nakamoto T, Tsuji K, Nifuji A, Miyazono K, Komori T, Hirai H, Noda M. Negative regulation of bone morphogenetic protein/Smad signaling by Cas-interacting zinc finger protein in osteoblasts. J Biol Chem. 2002 Aug 16;277(33):29840-6.
6 （229）	Haraguchi M, Tsujimoto H, Fukushima M, Higuchi I, Kuribayashi H, Utsumi H, Nakayama A, Hashizume Y, Hirato J, Yoshida H, Hara H, Hamano S, Kawaguchi H, Furukawa T, Miyazono K, Ishikawa F, Toyoshima H, Kaname T, Komatsu M, Chen ZS, Gotanda T, Tachiwada T, Sumizawa T, Miyadera K, Osame M, Yoshida H, Noda T, Yamada Y, Akiyama S. Targeted deletion of both thymidine phosphorylase and uridine phosphorylase and consequent disorders in mice. Mol Cell Biol. 2002 Jul;22(14):5212-21.
5 （228）	Sakuma R, Ohnishi Yi Y, Meno C, Fujii H, Juan H, Takeuchi J, Ogura T, Li E, Miyazono K, Hamada H. Inhibition of Nodal signalling by Lefty mediated through interaction with common receptors and efficient diffusion. Genes Cells. 2002 Apr;7(4):401-12.
4 （227）	Ring C, Ogata S, Meek L, Song J, Ohta T, Miyazono K, Cho KW. The role of a Williams-Beuren syndrome-associated helix-loop-helix domain-containing transcription factor in activin/nodal signaling. Genes Dev. 2002 Apr 1;16(7):820-35.
3 （226）	Suzawa M, Tamura Y, Fukumoto S, Miyazono K, Fujita T, Kato S, Takeuchi Y. Stimulation of Smad1 transcriptional activity by Ras-extracellular signal-regulated kinase pathway: a possible mechanism for collagen-dependent osteoblastic differentiation. J Bone Miner Res. 2002 Feb;17(2):240-8.
2 （225）	Miyazono K. A new partner for inhibitory Smads. Cytokine Growth Factor Rev. 2002 Feb;13(1):7-9.
1 （224）	Yagi K, Furuhashi M, Aoki H, Goto D, Kuwano H, Sugamura K, Miyazono K, Kato M. c-myc is a downstream target of the Smad pathway. J Biol Chem. 2002 Jan 4;277(1):854-61.